Compare · CRL vs NOTV
CRL vs NOTV
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and Inotiv Inc. (NOTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and NOTV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $10.81B, about 3876.7x NOTV ($2.8M).
- Over the past year, CRL is up 45.1% and NOTV is down 95.4% - CRL leads by 140.5 points.
- NOTV has been more active in the news (8 items in the past 4 weeks vs 3 for CRL).
- CRL has more recent analyst coverage (25 ratings vs 9 for NOTV).
- Company
- Charles River Laboratories International Inc.
- Inotiv Inc.
- Price
- $224.20-2.15%
- $0.08-14.45%
- Market cap
- $10.81B
- $2.8M
- 1M return
- +21.27%
- -72.65%
- 1Y return
- +45.06%
- -95.43%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 3
- 8
- Recent ratings
- 25
- 9
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Inotiv Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Latest CRL
- Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call
- Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
- Director Foster James C sold $16,875,000 worth of shares (75,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 70% to 31,596 units (SEC Form 4)
- Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
- Charles River upgraded by Morgan Stanley with a new price target
- Director Foster James C gifted 183,361 shares and received a gift of 183,361 shares, decreasing direct ownership by 62% to 106,596 units (SEC Form 4)
- Chief Executive Officer Girshick Birgit gifted 3,386 shares and received a gift of 3,386 shares, decreasing direct ownership by 9% to 36,013 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M gifted 1,529 shares and received a gift of 1,529 shares, decreasing direct ownership by 13% to 9,853 units (SEC Form 4)
- Director Barg Steven was granted 422 shares, increasing direct ownership by 15% to 3,287 units (SEC Form 4)
- EVP & Chief Financial Officer Coleman Glenn was granted 6,640 shares, increasing direct ownership by 31% to 27,752 units (SEC Form 4)
Latest NOTV
- Inotiv Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Inotiv Announces Confirmation of Plan of Reorganization
- Chief Financial Officer Taylor Beth A. covered exercise/tax liability with 5,864 shares, decreasing direct ownership by 4% to 139,616 units (SEC Form 4) (for tax liability)
- Chief Strategy Officer Sagartz John E covered exercise/tax liability with 6,071 shares, decreasing direct ownership by 0.83% to 729,626 units (SEC Form 4) (tax withholding)
- Chief Commercial Officer Hardy Adrian covered exercise/tax liability with 5,371 shares, decreasing direct ownership by 9% to 53,049 units (SEC Form 4) to satisfy withholding tax
- VP-Finance & Corp. Controller Freeman Jeffrey Brennan covered exercise/tax liability with 5,855 shares, decreasing direct ownership by 14% to 36,623 units (SEC Form 4) (tax withholding)
- EVP, GC, Sec'y & CCO Castetter Andrea covered exercise/tax liability with 5,800 shares, decreasing direct ownership by 11% to 49,200 units (SEC Form 4) (for tax liability)
- Chief Operating Officer Beattie John Gregory covered exercise/tax liability with 5,769 shares, decreasing direct ownership by 3% to 180,992 units (SEC Form 4) (withholding obligation)
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits